Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more



Ram Mullur, President

Ram is an accomplished executive with more than 25 years of broad industry experience, a proven trackrecord in business development and a thorough understanding of the medical isotopes and radiopharmaceuticals landscape.

He comes to Actineer from being Vice-President, Head of Isotope Business and an Executive Team member at Canadian Nuclear Laboratories. Under Ram’s leadership, Actineer’s Ac-225 program has recently hit important technology, commercial and corporate development milestones.

In his prior career role, Ram served as the Director and Head of Business Development at Jubilant Draxlmage, a global leader in radio-pharmaceuticals, where he was responsible for expanding the company’s commercial business into new products and technologies in the nuclear medicine and radiopharmaceutical field. This experience included exploring acquisition, investment and licensing initiatives, negotiating business contracts and pursuing strategic partnerships and collaborations.

Ram has also worked at Nordion (now BWXT-Medical Canada) as a Productions Operations Manager, as well as a Global Brand Manager for Medical Isotopes and Radiopharmaceuticals business. Ram received his MBA at McGill University, holds a M.Sc. degree in Chemistry and is certified in Canadian Risk Management.


Dr. Andreas Benischke, COO

Andreas joined ITM as a Project Manager for TechTransfers in 2023. Andreas studied Chemistry and Biochemistry in Munich and after his PhD he worked as a Process Chemist for API Synthesis in Switzerland.

After his stay close to Zurich, he worked for a Munich-Basel based Management Consultancy with focus on life science projects across the DACH region. Within these almost four years, Andreas collaborated with mid- and large-scale Pharma and Chemistry companies mainly in the field of Supply and Operations in highly cross-functional as well as multi-site project setups.

Since February 2023, Andreas major focus is on ITM's Ac-225 expansion strategy and thus, the joint venture Actineer in close collaboration with CNL. As of the launch of Actineer in October 2023, Andreas and Ram Mullur represent the Managing Directors as Chief Operating Officer COO and President. Together with the whole team, Actineer's Ac-225 program has recently hit important technology, commercial and corporate development milestones.


Actineer Quotes


Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.

Andreas Benischke, COO of Actineer

Two companies with long and distinguished histories of delivering medical isotopes to the global market have come together to help realize the potential that Ac-225-based radiopharmaceuticals’ promise. CNL has been fostering the Ac-225 market for years. The creation of the joint venture with ITM will accelerate advancing the technology needed to produce large quantities.

Ram Mullur, President of Actineer

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.

Fred Dermarkar, President and 

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.

Steffen Schuster, ITM CEO

Together with ITM, CNL has already made significant process towards our goal of bringing a next-generation medical isotope to the world market. With the launch of Actineer, we are poised to establish a reliable and large-scale supply of Ac-225 that we believe will unlock ground-breaking new cancer treatments. The entire team at CNL looks forward to applying their radiochemical expertise to the development of the new production process for Actinium-225 within this joint venture.

Joe McBrearty

Actinium-225 is a potent radionuclide utilized in targeted alpha therapies and holds great potential in the greater landscape of radionuclide therapy. Targeted alpha therapy with Actinium-225 will facilitate patient care in nuclear medicine by bringing new treatment opportunities to those who need it in addition to combining Radiopharmaceutical therapy possibilities with the established Lutetium-177. The expertise that ITM and CNL bring together is unique and essential for meeting the escalating demand for Actinium-225 across various applications.

Dr. Sebastian Marx, CBO of ITM